ArticleJournal of gastrointestinal cancer2025
Medullary Carcinoma of the Colon: Not as Favourable as Previously Thought?
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedullary carcinoma of the colon (MCC) is a rare, evolving subtype of colorectal cancer that is histologically and clinically distinct from poorly differentiated and undifferentiated adenocarcinoma. Comprehensive meta-analyses show that MCCs predominantly have a mismatch repair-deficient (MMRd) phenotype, which typically predicts a more favourable prognosis. CASE PRESENTATION: We present a unique case involving a male patient with an aggressive presentation of colon cancer. Histopathology supported a diagnosis of MCC, initially staged as T3N0M0. Shortly after resection, the patient presented with rapidly progressing metastatic disease involving brain and subcutaneous metastases and subsequent mortality.
conclusionMCC is an understudied subpopulation of colon cancers. Historically, the presence of MMRd in early-stage colon cancer predicts a favourable prognosis and also a lack of benefit from adjuvant chemotherapy. Whether this also extrapolates to MCCs remains unclear, and as such, the case presented highlights the uncertainty in the current evidence base. Further research is warranted to help inform robust clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.